Free Trial

AbbVie (ABBV) Earnings Date, Estimates & Call Transcripts

AbbVie logo
$175.58 +4.06 (+2.37%)
(As of 12/20/2024 05:45 PM ET)

AbbVie Latest Earnings Summary

Actual EPS
(Oct. 30)
$3.00 Beat By $0.08
Consensus EPS
(Oct. 30)
$2.92

AbbVie released Q3 2024 earnings on October 30, 2024, reporting an EPS of $3.00, which beat the consensus estimate of $2.92 by $0.08. Quarterly revenue rose 3.8% year-over-year to $14.46 billion, above analysts' expectations of $14.28 billion. With a trailing EPS of $2.88 and a P/E Ratio of 60.97, AbbVie's earnings are expected to grow 11.59% next year, from $10.96 to $12.23 per share.

Get AbbVie Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on AbbVie and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

ABBV Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

ABBV Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

AbbVie Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany Guidance
Q1 20244$2.21$10.93$4.402.180 - 2.220
Q2 20244$2.56$12.20$5.092.530 - 2.570
Q3 20244$2.85$13.31$5.492.920 - 2.960
Q4 20244$2.96$14.29$5.802.940 - 2.980
FY 202416$10.58$50.73$20.77 
Q1 20252$2.42$2.62$2.52 
Q2 20252$3.02$3.37$3.20 
Q3 20252$3.02$3.10$3.06 
Q4 20252$3.25$3.27$3.26 
FY 20258$11.71$12.36$12.04 
Q1 20261$2.85$2.85$2.85 
Q2 20261$3.29$3.29$3.29 
Q3 20261$3.54$3.54$3.54 

AbbVie Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
10/30/2024Q3 2024$2.92$3.00+$0.08$5.12$14.28B$14.46B
7/25/2024Q2 2024$2.57$2.65+$0.08$4.53$14.02B$14.46B
5/3/2024Q1 2024$2.26$2.31+$0.05$3.85$11.93B$12.31B
2/2/2024Q4 2023$2.76$2.79+$0.03$5.12$14.02B$14.30B
10/27/2023Q3 2023$2.86$2.95+$0.09$4.90$13.72B$13.93B
7/27/2023Q2 2023$2.79$2.91+$0.12$4.68$13.52B$13.87B
Has Trump Finally Gone Too Far? (Ad)

Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.

Register For The Webinar To Discover
4/27/2023Q1 2023$2.44$2.46+$0.02$4.79$12.23B$12.23B
2/9/2023Q4 2022$3.54$3.60+$0.06$5.82$15.30B$15.12B

AbbVie Earnings - Frequently Asked Questions

AbbVie (NYSE:ABBV) last announced its quarterly earning data on Wednesday, October 30, 2024. Learn more on ABBV's earnings history.

AbbVie updated its fourth quarter 2024 earnings guidance on Thursday, October, 31st. The company provided EPS guidance of 2.940-2.980 for the period, compared to the consensus EPS estimate of 2.950. The company issued revenue guidance of $14.8 billion-$14.8 billion, compared to the consensus revenue estimate of $14.6 billion.

In the previous quarter, AbbVie (NYSE:ABBV) reported $3.00 earnings per share (EPS) to beat the analysts' consensus estimate of $2.92 by $0.08. Learn more on analysts' earnings estimate vs. ABBV's actual earnings.

The conference call for AbbVie's latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for AbbVie's latest earnings report can be read online.
Read Transcript

AbbVie's earnings report can be found in their filing with the SEC.
View SEC filing

AbbVie (NYSE:ABBV) has a recorded annual revenue of $55.53 billion.

AbbVie (NYSE:ABBV) has a recorded net income of $4.86 billion. ABBV has generated $2.88 earnings per share over the last four quarters.

AbbVie (NYSE:ABBV) has a trailing price-to-earnings ratio of 60.97 and a forward price-to-earnings ratio of 16.02. The price/earnings-to-growth ratio is 1.92.

AbbVie's earnings are expected to grow from $10.96 per share to $12.23 per share in the next year, which is a 11.59% increase.

More Earnings Resources from MarketBeat



This page (NYSE:ABBV) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners